Is the business good?
How good a business is MLYS?
Mineralys Therapeutics, Inc. earns −71% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−71%
Return on invested capital · cost of capital 9.0% · 80 points below what the capital costs: growth destroys value
- Share count, year on year
- +29%
Share count, year on year · shareholders own a smaller slice than a year ago
Details›
- Net income, trailing twelve months
- −$350M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −71%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.